These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 33117695)

  • 1. The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma.
    Girard A; Vila Reyes H; Shaish H; Grellier JF; Dercle L; Salaün PY; Delcroix O; Rouanne M
    Front Oncol; 2020; 10():565086. PubMed ID: 33117695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the Performance of 18F-FDG PET/CT in Bladder Cancer: A Narrative Review of Current Evidence.
    Bacchiani M; Salamone V; Massaro E; Sandulli A; Mariottini R; Cadenar A; Di Maida F; Pradere B; Mertens LS; Longoni M; Krajewski W; Del Giudice F; D'Andrea D; Laukhtina E; Shariat SF; Minervini A; Moschini M; Mari A; On Behalf Of European Association Of Urology-Young Academic Urologists Eau-Yau Urothelial Carcinoma Working Group
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
    Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
    Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy.
    Rouanne M; Girma A; Neuzillet Y; Vilain D; Radulescu C; Letang N; Yonneau L; Hervé JM; Botto H; Le Stanc E; Lebret T
    Eur J Surg Oncol; 2014 Dec; 40(12):1724-30. PubMed ID: 25242381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer.
    Mertens LS; Mir MC; Scott AM; Lee ST; Fioole-Bruining A; Vegt E; Vogel WV; Manecksha R; Bolton D; Davis ID; Horenblas S; van Rhijn BW; Lawrentschuk N
    Urology; 2014 Feb; 83(2):393-8. PubMed ID: 24468513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of Molecular Imaging with 2-Deoxy-2-[Fluorine-18] Fluoro-DGlucose Positron Emission Tomography (18F-FDG PET) for Small Cell Lung Cancer (SCLC): A Radiation Oncology Perspective.
    Sager O; Dincoglan F; Demiral S; Uysal B; Gamsiz H; Elcim Y; Gundem E; Dirican B; Beyzadeoglu M
    Curr Radiopharm; 2019; 12(1):4-10. PubMed ID: 30465520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated analysis of
    Girard A; Rouanne M; Taconet S; Radulescu C; Neuzillet Y; Girma A; Beaufrere A; Lebret T; Le Stanc E; Grellier JF
    Eur Radiol; 2019 Aug; 29(8):4286-4293. PubMed ID: 30666449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
    Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
    Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-fluoro-2-deoxy-2-d-glucose PET-CT (FDG PET-CT) in staging of high-risk renal and urothelial bladder cancers (COPPER-T) trial protocol.
    Jena R; Bhargava P; Tripathi S; Taywade S; Yadav T; Sandhu AS; Singh M; Navriya SC; Bhirud DP; Aggarwal A; Choudhary GR
    BJUI Compass; 2023 Nov; 4(6):662-667. PubMed ID: 37818027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography in ovarian cancer: 18F-deoxy-glucose and 16alpha-18F-fluoro-17beta-estradiol PET.
    Yoshida Y; Kurokawa T; Tsujikawa T; Okazawa H; Kotsuji F
    J Ovarian Res; 2009 Jun; 2(1):7. PubMed ID: 19527525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
    Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging.
    Caresia Aroztegui AP; García Vicente AM; Alvarez Ruiz S; Delgado Bolton RC; Orcajo Rincon J; Garcia Garzon JR; de Arcocha Torres M; Garcia-Velloso MJ;
    Tumour Biol; 2017 Oct; 39(10):1010428317728285. PubMed ID: 29025377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma.
    Triviño Ibáñez EM; Muros MA; Torres Vela E; Llamas Elvira JM
    Endocrine; 2016 Mar; 51(3):490-8. PubMed ID: 26224589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study.
    Zattoni F; Incerti E; Colicchia M; Castellucci P; Panareo S; Picchio M; Fallanca F; Briganti A; Moschini M; Gallina A; Karnes JR; Lowe V; Fanti S; Schiavina R; Rambaldi I; Ficarra V; Evangelista L
    Abdom Radiol (NY); 2018 Sep; 43(9):2391-2399. PubMed ID: 29302738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer.
    Orsaria P; Chiaravalloti A; Caredda E; Marchese PV; Titka B; Anemona L; Portarena I; Schillaci O; Petrella G; Palombi L; Buonomo OC
    Anticancer Res; 2018 Dec; 38(12):6639-6652. PubMed ID: 30504372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.